JP2020511541A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020511541A5 JP2020511541A5 JP2020500785A JP2020500785A JP2020511541A5 JP 2020511541 A5 JP2020511541 A5 JP 2020511541A5 JP 2020500785 A JP2020500785 A JP 2020500785A JP 2020500785 A JP2020500785 A JP 2020500785A JP 2020511541 A5 JP2020511541 A5 JP 2020511541A5
- Authority
- JP
- Japan
- Prior art keywords
- humanized antibody
- antibody
- humanized
- seq
- antibody according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023098123A JP7624478B2 (ja) | 2017-03-20 | 2023-06-14 | 癌治療において壊死を標的とするヒト化抗核抗体 |
| JP2025008079A JP2025066768A (ja) | 2017-03-20 | 2025-01-20 | 癌治療において壊死を標的とするヒト化抗核抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762473554P | 2017-03-20 | 2017-03-20 | |
| US62/473,554 | 2017-03-20 | ||
| PCT/US2018/023123 WO2018175310A1 (en) | 2017-03-20 | 2018-03-19 | Humanized anti-nuclear antibodies for targeting necrosis in cancer therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023098123A Division JP7624478B2 (ja) | 2017-03-20 | 2023-06-14 | 癌治療において壊死を標的とするヒト化抗核抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020511541A JP2020511541A (ja) | 2020-04-16 |
| JP2020511541A5 true JP2020511541A5 (cg-RX-API-DMAC10.html) | 2021-04-30 |
| JP7299209B2 JP7299209B2 (ja) | 2023-06-27 |
Family
ID=63584724
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020500785A Active JP7299209B2 (ja) | 2017-03-20 | 2018-03-19 | 癌治療において壊死を標的とするヒト化抗核抗体 |
| JP2023098123A Active JP7624478B2 (ja) | 2017-03-20 | 2023-06-14 | 癌治療において壊死を標的とするヒト化抗核抗体 |
| JP2025008079A Pending JP2025066768A (ja) | 2017-03-20 | 2025-01-20 | 癌治療において壊死を標的とするヒト化抗核抗体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023098123A Active JP7624478B2 (ja) | 2017-03-20 | 2023-06-14 | 癌治療において壊死を標的とするヒト化抗核抗体 |
| JP2025008079A Pending JP2025066768A (ja) | 2017-03-20 | 2025-01-20 | 癌治療において壊死を標的とするヒト化抗核抗体 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US11384157B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3601364A4 (cg-RX-API-DMAC10.html) |
| JP (3) | JP7299209B2 (cg-RX-API-DMAC10.html) |
| KR (2) | KR20240148849A (cg-RX-API-DMAC10.html) |
| CN (2) | CN110461878B (cg-RX-API-DMAC10.html) |
| AU (2) | AU2018237046B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3056703A1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2018175310A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240148849A (ko) * | 2017-03-20 | 2024-10-11 | 캔서 테라퓨틱스 래버러토리즈 인코포레이티드 | 암 치료법에서 괴사를 표적화하기 위한 인간화 항-핵 항체 |
| CN115819604B (zh) * | 2022-09-09 | 2025-04-15 | 季华实验室 | 抗双链dna抗体、核苷酸片段、磁珠及提取外周血游离dna的方法 |
| LU103248B1 (en) | 2024-02-19 | 2025-08-19 | Stratec Se | Container handling device |
| WO2025194038A1 (en) * | 2024-03-15 | 2025-09-18 | Caris Science, Inc. | Antibody compositions and methods for targeting extracellular nucleosome proteins |
| US20260027155A1 (en) | 2024-07-23 | 2026-01-29 | Immunitybio, Inc. | Compositions and methods related to potent cytotoxic m-cenk cells from cd3/cd14-depleted apheresis products |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8795672B2 (en) * | 2003-02-14 | 2014-08-05 | University Of Southern California | Compositions and methods for cancer immunotherapy |
| NZ581468A (en) * | 2007-06-25 | 2012-09-28 | Esbatech Alcon Biomed Res Unit | Methods of modifying antibodies, and modified antibodies with improved functional properties |
| US9260517B2 (en) * | 2009-11-17 | 2016-02-16 | Musc Foundation For Research Development | Human monoclonal antibodies to human nucleolin |
| GB201220242D0 (en) * | 2012-11-09 | 2012-12-26 | Fusion Antibodies Ltd | Antibody |
| WO2015106290A1 (en) * | 2014-01-13 | 2015-07-16 | Valerion Therapeutics, Llc | Internalizing moieties |
| US10383945B2 (en) * | 2015-02-18 | 2019-08-20 | The United States of America as Represented by the Department of Verterans Affairs | Methods for DNA-dependent targeting of a cell permeant antibody |
| US20180194831A1 (en) * | 2015-07-10 | 2018-07-12 | Ohio State Innovation Foundation | Methods and compositions relating to anti-nucleolin recombinant immunoagents |
| MX2019004681A (es) * | 2016-10-21 | 2019-10-07 | Altor Bioscience Corp | Moleculas basadas en il-15 multimericas. |
| KR20240148849A (ko) | 2017-03-20 | 2024-10-11 | 캔서 테라퓨틱스 래버러토리즈 인코포레이티드 | 암 치료법에서 괴사를 표적화하기 위한 인간화 항-핵 항체 |
-
2018
- 2018-03-19 KR KR1020247027978A patent/KR20240148849A/ko active Pending
- 2018-03-19 US US16/496,177 patent/US11384157B2/en active Active
- 2018-03-19 CN CN201880019797.6A patent/CN110461878B/zh active Active
- 2018-03-19 WO PCT/US2018/023123 patent/WO2018175310A1/en not_active Ceased
- 2018-03-19 JP JP2020500785A patent/JP7299209B2/ja active Active
- 2018-03-19 EP EP18770253.5A patent/EP3601364A4/en active Pending
- 2018-03-19 AU AU2018237046A patent/AU2018237046B2/en active Active
- 2018-03-19 KR KR1020197030327A patent/KR102698752B1/ko active Active
- 2018-03-19 CN CN202310018919.2A patent/CN115947859A/zh active Pending
- 2018-03-19 CA CA3056703A patent/CA3056703A1/en active Pending
-
2022
- 2022-06-14 US US17/839,953 patent/US12258421B2/en active Active
-
2023
- 2023-06-14 JP JP2023098123A patent/JP7624478B2/ja active Active
-
2024
- 2024-11-07 AU AU2024259793A patent/AU2024259793A1/en active Pending
-
2025
- 2025-01-20 JP JP2025008079A patent/JP2025066768A/ja active Pending
- 2025-01-21 US US19/032,799 patent/US20250215114A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018133708A (ru) | Антитела, обладающие специфичностью к btla, и их использование | |
| JP2019511201A5 (cg-RX-API-DMAC10.html) | ||
| JP2016128474A5 (cg-RX-API-DMAC10.html) | ||
| JP2016517277A (ja) | ＴＮＦαに対して指向された二重特異的結合タンパク質 | |
| JP2022530404A5 (cg-RX-API-DMAC10.html) | ||
| JP2020500003A5 (cg-RX-API-DMAC10.html) | ||
| US20210087243A1 (en) | Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide | |
| CN108368160A (zh) | 淀粉样蛋白β中的C-末端表位及其构象选择性抗体 | |
| JP2015529641A5 (cg-RX-API-DMAC10.html) | ||
| JP7836270B2 (ja) | 抗ｄｏｔａ／抗腫瘍抗原二重特異性抗体による事前標的化放射免疫治療のためのｄｏｔａ－ハプテン組成物 | |
| US12258421B2 (en) | Humanized anti-nuclear antibodies for targeting necrosis in cancer therapy | |
| CN108350050A (zh) | 淀粉样蛋白β中的表位及其构象选择性抗体 | |
| JP2022542670A5 (cg-RX-API-DMAC10.html) | ||
| CN112243381B (zh) | 抗bcma car抗体、缀合物和使用方法 | |
| CN108350052A (zh) | 淀粉样蛋白β中间区域中的表位及其构象选择性抗体 | |
| CN108084265A (zh) | 特异性结合人的5t4抗原的全人源单域抗体及其应用 | |
| JP2014515600A5 (cg-RX-API-DMAC10.html) | ||
| JP2021516254A5 (cg-RX-API-DMAC10.html) | ||
| KR102486507B1 (ko) | 플렉틴-1 결합 항체 및 그의 용도 | |
| Yakushiji et al. | Novel single‐chain variant of antibody against mesothelin established by phage library | |
| AR077941A1 (es) | Anticuerpos contra osteopontina | |
| CN108289889A (zh) | 靶向癌症干细胞和治疗侵袭性癌症的抗体 | |
| TWI696632B (zh) | 抗-類egf結構域多重6(egfl6)抗體及其於癌症診斷及治療中之應用 | |
| US20110171216A1 (en) | Monoclonal antibodies specific for pancreatic neoplasia cells | |
| US20110256060A1 (en) | Monoclonal antibody and its use for the identification of the oncofetal isoform of fibronectin (b-fn) for diagnosis or therpay |